Overexpression of p53 protein in human tumors

Medical Molecular Morphology

Volumn 45, Issue 3, 2012, Pages 115-123

  Inoue, Keiji ^a   Kurabayashi, Atsushi ^a   Shuin, Taro ^a   Ohtsuki, Yuji ^b   Furihata, Mutsuo ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b Division of Pathology Mastuyama shimin Hospital   (Japan)

Author keywords

Malignant tumor; P53; TP53

Indexed keywords

MUTANT PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEIN P63; PROTEIN P73;

CANCER PROGNOSIS; CARCINOGENESIS; EPIGENETICS; GENE; GENE AMPLIFICATION; GENETIC TRANSCRIPTION; GENOME; HOMEOSTASIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; REGULATORY MECHANISM; REVIEW; TP53 GENE; TUMOR SUPPRESSOR GENE;

CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84871423991     PISSN: 18601480     EISSN: 18601499     Source Type: Journal    
DOI: 10.1007/s00795-012-0575-6     Document Type: Review

References (114)

1. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607-614 (Pubitemid 34556481)
2. Hainaut P, Hollstein M (2000) p53 and human cancer: the fi rst ten thousand mutations. Adv Cancer Res 77:81-137 (Pubitemid 29439303)
3. Kropveld A, Rozemuller EH, Leppers FG, Scheidel KC, de Weger RA, Koole R, Hordijk GJ, Slootweg PJ, Tilanus MG (1999) Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of the head and neck squamous cell cancers. Lab Invest 79:347-353 (Pubitemid 29166450)
4. Lane DP, Benchimol S (1990) p53: oncogene or anti-oncogene? Genes Dev 4:1-8
5. Soussi T, Caron de Fromentel C, May P (1990) Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952
6. Eliyahu D, Raz A, Gruss P, Givol D, Oren M (1984) Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (Lond) 312:646-649 (Pubitemid 15218336)
7. Jenkins JR, Rudge K, Currie GA (1984) Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature (Lond) 312:651-654 (Pubitemid 15218338)
8. Parada LF, Land H, Weinberg RA, Wolf D, Rotter V (1984) Cooperation between gene encoding p53 antigen and ras in cellular transformation. Nature (Lond) 312:649-651 (Pubitemid 15218337)
9. Fearon ER, Hamilton SR, Vogelstein B (1987) Clonal analysis of human colorectal tumors. Science 238:193-197 (Pubitemid 17139720)
10. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal tumor development. N Engl J Med 319:525-532
11. Yokota J, Wada M, Shimosato Y, Terada M, Sugimura T (1987) Loss of heterozygosity on chromosomes 3, 1, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci USA 84:9252-9256 (Pubitemid 18055342)
12. James CD, Carlbom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP, Cavenee WK (1988) Clonal genomic alterations in glioma malignancy stages. Cancer Res 48:5546-5551
13. Mackay J, Steel CM, Elder PA, Forrest AP, Evans HJ (1988) Allele loss on short arm of chromosome 17 in breast cancer. Lancet 2:1384-1385 (Pubitemid 19004481)
14. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Baker DF, Nakamura Y, White R, Vogelstein B (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217-221 (Pubitemid 19110302)
15. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumor types. Nature (Lond) 342:705-708 (Pubitemid 20001591)
16. Finlay CA, Hinds P, Levine A (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093 (Pubitemid 19169804)
17. Mercer WE, Amin M, Sauve GJ (1990) Wild type human p53 is antiproliferative in SV40-transformed hamster cells. Oncogene 5:973-980
18. Iggo R, Gatter K, Bartek J (1990) Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675-679 (Pubitemid 20089305)
19. Gannon JV, Greaves R, Iggo R (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specifi c for the mutant form. EMBO J 9:1595-1602
20. Bartek J (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699-1703 (Pubitemid 21924277)
21. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM (1986) Localization of gene for human p53 tumour antigen to band 17p13. Nature (Lond) 320:84-85 (Pubitemid 16105254)
22. McBride OW, Merry D, Givol D (1986) The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 83:130-134 (Pubitemid 16141627)
23. Miller C, Mohandas T, Wolf D (1986) Human p53 gene localized to short arm of chromosome 17. Nature (Lond) 319:783-784 (Pubitemid 16145035)
24. Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355 (Pubitemid 24259959)
25. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53 (Pubitemid 21917115)
26. Caron de Fromentel C, Soussi T (1992) TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4:1-15
27. Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature (Lond) 351:453-456
28. Bullock AN, Fersht AR (2001) Rescuing the function of mutant p53. Nat Rev Cancer 1:68-76 (Pubitemid 33741882)
29. Fields S, Jang SK (1990) Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046-1049
30. Raycroft L, Wu H, Lozano G (1990) Transcriptional activation by wild-type but not transforming mutations of the p53 antioncogene. Science 249:1049-1051
31. Stürzbecher HW, Brain R, Addison C, Rudge K, Remm M, Grimaldi M, Keenan E, Jenkins JR (1992) A C-terminal a-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1513-1523
32. Iwabuchi K, Li B, Bartel P, Fields S (1993) Use of the two-hybrid to identify the domain of p53 involved in oligomerization. Oncogene 8:1693-1696 (Pubitemid 23189068)
33. Hollstein M, Hainaut P (2010) Massively regulated genes: the example of TP53. J Pathol 220:164-173
34. Courtois S, de Fromentel CC, Hainaut P (2004) p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene 23:631-638 (Pubitemid 38241264)
35. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19:2122- 2137 (Pubitemid 41330315)
36. Marcel V, Hainaut P (2009) p53 isoforms - a conspiracy to kidnap p53 tumor suppressor activity? Cell Mol Life Sci 66:391-406
37. Lane DP, Crawford LV (1979) T-antigen is bound to host protein in SV40-transformed cells. Nature (Lond) 278:261-263 (Pubitemid 9129076)
38. Linzer DIH, Levine AJ (1979) Characterization of a 54 K dalton cellular SV40 tumour antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52 (Pubitemid 9188209)
39. Werness BA, Levine AJ, Howley P (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79
40. Szekely L, Selivanova G, Magnusson KP, Klein G, Wiman KG (1993) EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 90:5455-5459 (Pubitemid 23176179)
41. Sarnow P, Ho YS, Williams J, Levine AJ (1982) Adenovirus E1b-58 kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28:387-394 (Pubitemid 12132769)
42. Feitelson MA, Zhu M, Duan LX, London WT (1993) Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8:1109-1117 (Pubitemid 23129832)
43. Symonds H, Chen JD, Van Dyke T (1991) Complex formation between the lymphotropic papovavirus large tumor antigen and the tumor suppressor protein p53. J Virol 65:5417-5424
44. Rogel A, Popliker M, Webb CG, Oren M (1985) p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 5:2851-2855 (Pubitemid 15237110)
45. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papilloma virus type 16 and 18 promotes degradation of p53. Cell 63:1129-1136 (Pubitemid 120035062)
46. Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kessler B, La Thanque NB (2008) Arginine methylation regulates the p53 response. Nat Cell Biol 10:1431-1439
47. Han MK, Song EK, Guo Y, Ou X, Mantel C, Broxmeyer HE (2008) SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell 2:241-251 (Pubitemid 351298591)
48. Gurney EG, Harrison RO, Fennol J (1980) Monoclonal antibodies against simian virus 40 T antigens: evidence for distinct subclasses of large T antigen and for similarities among nonviral T antigens. J Virol 34:752-763
49. Dippold WG, Jay G, DeLeo A, Khoury G, Old LJ (1981) p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Acad Sci USA 78:1695-1699 (Pubitemid 11114249)
50. Rotter V, Abutbul H, Ben-Ze'ev A (1983) p53 transformationrelated protein accumulates in the nucleus of transformed fi broblasts in association with the chromatin and is found in the cytoplasm of non-transformed fi broblasts. EMBO J 2:1041-1047
51. Deppert W, Hang M (1986) Evidence for free and metabolically stable p53 protein in nuclear subfractions of simian virus 40- transformed cells. Mol Cell Biol 6:2233-2240
52. Shaulsky G, Ben-Ze'ev A, Rotter V (1990) Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene 5:1707-1711 (Pubitemid 120034693)
53. Puvion E, Duthu A, Harper F, Ehrhart JC, Viron A, May P (1988) Intranuclear distribution of SV40 large T-antigen and transformation- related protein p53 in abortively infected cells. Exp Cell Res 177:73-89
54. Pietrancosta N, Moumen A, Dono R, Lingor P, Planchamp V, Lamballe F, Bähr M, Kraus JL, Maina F (2006) Imino-tetrahydrobenzothiazole derivatives as p53 inhibitors: discovery of a highly potent in vivo inhibitor and its action mechanism. J Med Chem 49:3645-3652 (Pubitemid 43902469)
55. Laptenko O, Prives C (2006) Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 13:951-961
56. Barboza JA, Iwakuma T, Terzian T, El-Naggar AK, Lozano G (2008) Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res 6:947-954
57. Chi SW, Lee SH, Kim DH, Ahn MJ, Kim JS, Woo JY, Torizawa T, Kainosho M, Han KH (2005) Structural details on mdm2-p53 interaction. J Biol Chem 280:38795-38802 (Pubitemid 43853782)
58. Ashcroft M, Taya Y, Vousden KH (2000) Stress signals utilize multiple pathways to stabilize p53. Mol Cel Biol 20:3224-3233 (Pubitemid 30215034)
59. Shieh SY, Ikeda M, Taya Y, Prives C (1997) DNA damage-induced phosphrylation of p53 alleviates inhibition by MDM2. Cell 91:325-334 (Pubitemid 27467963)
60. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C (2000) The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14:289-300 (Pubitemid 30106484)
61. Appella E, Anderson CW (2001) Post-translational modifi cations and activation of p53 by genotoxic stresses. Eur J Biochem 268:2764-2772 (Pubitemid 32862957)
62. Ashcroft M, Kubbutat MH, Vousden KH (1999) Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 19:1751-1758 (Pubitemid 29098233)
63. Ayed A, Mulder FA, Yi GS, Lu Y, Kay LE, Arrowsmith CH (2001) Latent and active p53 are identical in conformation. Nat Struct Biol 8:756-760 (Pubitemid 32803591)
64. Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137:609- 622
65. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, McMahon SB (2006) Acethylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24:841-851 (Pubitemid 44960096)
66. Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y, Nemoto S, Finkel T, Gu W, Cress WD, Chen J (2006) Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 8:1025-1031 (Pubitemid 44314735)
67. Books CL, Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15:164-171 (Pubitemid 36332191)
68. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W (2008) Acetylation is indispensable for p53 activation. Cell 133:612-626 (Pubitemid 351636297)
69. Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C (1991) Wild-type but not mutant p53 immunopurifi ed proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65:1083-1091 (Pubitemid 121001696)
70. Kruse JP, Gu W (2008) SnapShot: p53 posttranslational modifi cations. Cell 133:930-930, e1
71. Carter S, Vousden KH (2009) Modifi cations of p53: competing for the lysines. Curr Opin Genet Dev 19:18-24
72. Weisz L, Oren M, Rotter V (2007) Transcription regulation by mutant p53. Oncogene 26:2202-2211 (Pubitemid 46536644)
73. Benchimol S, Pim D, Crawford L (1982) Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J 7:1055-1062
74. Porter PL, Gown AM, Kramp SG, Coltrera MD (1992) Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fi xed, embedded tissue. Am J Pathol 140:145-153
75. Furihata M, Sonobe H, Ohtsuki Y (1995) The aberrant p53 protein (review). Int J Oncol 6:1209-1226
76. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-872 (Pubitemid 40017691)
77. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847-860 (Pubitemid 40017690)
78. Song H, Hollstein M, Xu Y (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9:573-580 (Pubitemid 46696539)
79. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22:1337-1344 (Pubitemid 351717524)
80. McLure KG, Lee PW (1998) How p53 binds DNA as a tetramer. EMBO J 17:3342-3350 (Pubitemid 28279508)
81. Milner J, Medcalf AJ (1991) Co-translation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765-774 (Pubitemid 121001308)
82. Hinds P, Finlay C, Levine AJ (1989) Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63:739-746 (Pubitemid 19057240)
83. Varley JM, Thorncroft M, McGown G, Appleby J, Kelsey AM, Tricker KJ, Evans DGR, Birch JM (1997) A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li- Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 14:865-871 (Pubitemid 27100031)
84. Erber R, Conradt C, Homann N, Enders C, Finck M, Dietz A, Weidauer H, Bosch FX (1998) TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 16:1671-1679 (Pubitemid 28175048)
85. Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, Varley JM (1998) Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 17:1061-1068 (Pubitemid 28444590)
86. Xu Y (2006) DNA damage: a trigger of innate immunity but a requirement for adaptive immune homeostasis. Nat Rev Immunol 6:261-270
87. Wolf D, Admon S, Oren M (1984) Abelson murine leukemia virustransformed cells that lack p53 protein synthesis express aberrant p53 mRNA species. Mol Cell Biol 4:552-558
88. Shaulsky G, Goldfinger N, Rotter V (1991) Alterations in tumor development in vivo mediated by expression of wild-type or mutant p53 proteins. Cancer Res 51:5232-5237
89. Crook T, Marston NJ, Sara EA, Vousden KH (1994) Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79:817-827 (Pubitemid 24371972)
90. Wolf D, Harris N, Rotter V (1984) Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell 38:119-126 (Pubitemid 15216541)
91. Shaulsky G, Goldfinger N, Rotter V (1991) Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res 51:5232-5237
92. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ (1993) Gain of function mutations in p53. Nat Genet 4:42-46 (Pubitemid 23165910)
93. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplifi cation in cells with mutant p53 alleles. Cell 70:937-948
94. Hartwell L (1992) Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546
95. Di Como CJ, Gaiddon C, Prives C (1999) p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 19:1438-1449 (Pubitemid 29046885)
96. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21:1874-1887 (Pubitemid 32156407)
97. Deyoung MP, Ellisen LW (2007) p63 and p73 in human cancer: defi ning the network. Oncogene 26:5169-5183 (Pubitemid 47237632)
98. Weisz L, Oren M, Rotter V (2007) Transcription regulation by mutant p53. Oncogene 26:2202-2211 (Pubitemid 46536644)
99. Kim E, Deppert W (2004) Transcriptional activities of mutant p53: when mutations are more than a loss. J Cell Biochem 93: 878-886 (Pubitemid 44264143)
100. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G (2007) Mutant p53: an oncogenic transcription factor. Oncogene 26:2212-2219 (Pubitemid 46536646)
101. Di Agostino S, Strano S, Emilliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, Piaggio G (2006) Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10:191-202 (Pubitemid 44311070)
102. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 94: 23-28
103. Fearon ER, Vogelstein BA (1990) A genetic model for colorectal tumorigenesis. Cell 61:759-767
104. Woolner LB (1986) Lung. In: Henson DE, Albores-Saavedra J (eds) The pathology of incipient neoplasia. Saunders, Philadelphia, pp 57-85
105. Auerbach O, Hammond E, Carfi nkel L (1979) Changes in bronchial epitheium in relation to cigarette smoking, 1955-1960 vs.970-1977. N Engl J Med 300:381-386 (Pubitemid 9134282)
106. Olivier M, Hainaut P, Borresen-Dale AL (2005) Prognostic and predictive value of TP53 mutations in human cancer. In: Hainaut P, Wiman KG (eds) 25 years of p53 research. Springer, New York, pp 321-338
107. Yamasaki I, Furihata M, Ohtsuki Y, Yamashita M, Morioka M, Shuin T (1996) Overexpression of MDM2 and p53 protein is infrequently but signifi cantly associated with progression of human prostatic adenocarcinoma. Oncol Rep 3:925-929 (Pubitemid 26323754)
108. Matsumoto M, Furihata M, Kurabayashi A, Ohtsuki Y (2004) Phosphorylation state of tumor-suppressor gene p53 product overexpressed in skin tumors. Oncol Rep 12:1039-1043
109. Matsumoto M, Furihata M, Kurabayashi A, Sasaguri S, Araki K, Hayashi H, Ohtsuki Y (2004) Prognostic signifi cance of serine 392 phosphorylation in overexpressed p53 protein in human esophageal squamous cell carcinoma. Oncology 67:143-150 (Pubitemid 39482683)
110. Furihata M, Inoue K, Ohtsuki Y, Hashimoto H, Terao N, Fujita Y (1993) High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res 53:4823-4827 (Pubitemid 23326173)
111. Furihata M, Takeuchi T, Matsumoto M, Kurabayashi A, Ohtsuki Y, Terao N, Kuwahara M, Shuin T (2002) p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res 8:1192-1195 (Pubitemid 34517658)
112. Ryu MH, Kang YK, Jang SJ, Kim TW, Lee H, Kim JS, Park YH, Lee SS, Ryoo BY, Chang HM, Lee JL, Yook JH, Kim BS, Lee JS (2007) Prognostic signifi cance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours. Histopathology (Oxf) 51:379-389 (Pubitemid 47301630)
113. Bartel F, Jung J, Böhnke A, Gradhand E, Zeng K, Thomssen C, Hauptmann S (2008) Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res 14:89-96 (Pubitemid 351377982)
114. Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 fi eld. Cancer (Phila) 9:701-713